Safety Study of Abatacept to Treat Rheumatoid Arthritis (A)
Completed
- Conditions
- Rheumatoid Arthritis
- Registration Number
- NCT01088321
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
The purpose of this study is to compare the incidence rates of infection among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 81332
Inclusion Criteria
- Diagnosis of rheumatoid arthritis
- Claims indicating infusion, injection, or dispensing of abatacept, a DMARD, or a BDM
- Age 18 years or older at the time of drug initiation
- Enrollment in the health plan at least 6 continuous months leading up to the time of study drug initiation
Read More
Exclusion Criteria
- Below 18 years of age at the time of BDM or DMARD initiation
- Lacking six months of continuous enrollment prior to the initiation of one of the study drugs
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Infections, specifically hospitalized infection, hospitalized pneumonia, hospitalized and/or IV treated pneumonia, tuberculosis, herpes zoster, and opportunistic infection Every four months throughout the study
- Secondary Outcome Measures
Name Time Method Anaphylactic reactions Every four months throughout the study Concomitant biologic use Every four months throughout the study Multiple sclerosis, lupus, and psoriasis Every four months throughout the study